Table 4

Mean difference in, and 95% confidence interval for, change from baseline hearing level in dB for patients receiving regimens containing ZDV or ddI, estimated by GEE model adjusting for time since beginning therapy, baseline hearing level, and age.*

Low Frequency PTA†

High Frequency PTA


All patients

Age < 35 years

Age ≥ 35 years

All patients

Age < 35 years

Age ≥ 35 years


ZDV

4.0 (-1.4 – 9.5)

3.9 (-0.6 – 8.4)

4.5 (-2.1 – 11.0)

p = 0.70

1.2 (-1.2 – 3.5)

1.5 (-1.7 – 4.8)

0.80 (-2.4 – 4.0)

p = 0.75

ddI

- 2.6 (-6.1 – 0.9)

p = 0.91

- 0.6 (-2.5 – 1.2)

- 5.4 (-13.8 – 3.1)

p = 0.31

0.2 (-3.1 – 2.7)

- 0.2 (-3.3 – 2.8)

- 0.1 (-3.7 – 3.5)

p = 0.95

Combined

(per 100 drug-days) ‡

- 0.08 (-1.2 – 1.0

) p = 0.89

-0.28 (-0.80 – 1.4)

p = 0.61

-0.45 (-1.6 – 0.69)

p = 0.44

-0.047 (-1.4 – 1.3)

p = 0.75

0.098 (-2.0 – 1.3)

p = 0.92

-0.22 (-1.6 – 1.2)

p = 0.70


*A positive value indicates worsening hearing level; a negative value indicates improved hearing level.

†Pure Tone Average

‡Cumulative total number of days each patient took ZDV and ddI

Schouten et al. BMC Infectious Diseases 2006 6:28   doi:10.1186/1471-2334-6-28

Open Data